StemCell Therapy

Research can take a long time; therefore, we cannot guarantee that we will find information in your sample to return to you. As more samples are processed and genotyping is completed, the Biobank may find information that is medically important for some participants. This information is about genetic variations or changes in DNA that may affect how a person reacts to certain types of medications or that may increase risk of certain diseases, such as cancer or heart disease. For many of these diseases, there are medical options to reduce risk or manage the effects of disease.

If we learn something about your sample, such as information on your risk of certain diseases or health conditions, how you may respond to medications or your risk of being a carrier of certain diseases, we may be able to return this to you. We will ask your permission first before returning any information to you. However, not everyone will have this information, so we cannot guarantee that everyone will receive results

See original here:
Colorado Center for Personalized Medicine

Personalized medicine is gaining recognition due to limitations with standard diagnosis and treatment; many areas of medicine, from cancer to psychiatry, are moving towards tailored treatment for individual patients based on their genetic signatures and clinical characteristics. Advances in whole genome sequencing have allowed the identification of genes involved in a large number of diseases, and biomarkers that indicate disease severity or susceptibility to treatment are increasingly being characterized. The continued identification of new genes and biomarkers specific to disease subtypes and individual patients is essential for translation into personalized medicine, in terms of estimating both disease risk and response to therapy. This article collection covers recent advances in personalized medicine across all areas of medical science and clinical practice, demonstrating that patient-tailored treatment is being employed for some diseases, whereas more work is required to translate scientific advances into the clinic for others. We are seeking submissions of original research, reviews and debates offering insights into new advances in this exciting area of medicine.

Read the original:
Personalized medicine: genes, biomarkers and tailored treatment

Personalized medicine are drugs that are based on individual patient or intended patient groups carrying certain biomarkers and are created to cater the requirement of an individual patient based on the response produced by the patient suffering from a particular disease. The personalized medicines are currently in focus due to their effectiveness in cancer patients and patients suffering from rare genetic disorders. The fact that this approach could do away with the One Size Fits All approach leads to anticipations regarding higher treatment effectiveness through customization of prevention, prediction and treatments. In this regard, funds worth EUR 1 Bn has been invested by the EU as of 2015, focused on the development of personalized medicine, through its Seventh Framework Program for Research and Technological Innovation. The EU is also known to be coordinating with the member states on Health Technology Assessment for better understanding on cost-benefit-efficiency of including personalized medicines in their respective health systems. Constructive dialogue among global stakeholders could streamline the clinical trial processes and regulations regarding the same over the forthcoming years.

Personalized Medicine Market: Drivers & Restraints

Personalized medicine market is expected to witness rapid growth due to increasing disease incidence and deep focus of creating medicines for cancer patients where effectiveness has been proved to be higher as compared to other therapies. Rapid results & customized effects, lower probability of medication flaws and adverse drug reactions are some of the other factors that could create suitable traction in both R&D and revenue potential for these medicines. Favorable policies of the governments in relation to the personalized medicine will also add incremental opportunity to exploit this market. Recent developments in the pharmacogenomics are expected to create suitable environment for developing drugs, which are specific to one patient or group. Development of genetic databases could provide additional boost to the market. Upcoming therapeutic application opportunities in fields such as cardio-renal, neurology, antiviral, pulmonary, psychiatry among others could create R&D traction across all regions.

Complex nature of the drugs, high development costs, sub-optimal development framework and inter-patient variability of effects are some of the restraints that could hamper revenue growth of the personalized medicines market over the forthcoming years.

Personalized Medicine Market: Segmentation

This market can be segmented on the basis of Therapeutic area, End user and Application as follows:

Segmentation based on Therapeutic area

Oncology

Neurology

Cardiology

Antiviral

Psychiatry

Others

Segmentation based on End User

Hospitals

Molecular Diagnostic Laboratories and Testing facilities

Academic Institutes, clinical care and Research Laboratories

Contract Research Organizations

Bio and health informatics companies

Others (Service providers, partners, venture capitalists, etc.)

Segmentation based on Application

Companion Diagnostics

Biomarker identification

Health Informatics

Clinical Research

Personalized Medicine Market: Overview & Region wise Outlook

This market is mainly driven by increasing disease incidence of various cancers and other autoimmune diseases during the forecast period. The major growth in revenues is estimated to be contributed by markets in North America followed by Europe. This can be attributed to increasing pool of cancer patients along with high healthcare per capita expenditure. The ongoing research and legal initiatives in personalized medicine in Japan could promote the market growth in the country during the forecast period. In markets in Asia pacific and Latin America regions, accelerated development of R&D infrastructure could lead bigger drug makers to create their regional R&D centers focused on personalized medicine during the forecast period. The opening up research in the bioinformatics industry and active peer levels discussion and dialogues are factors that contribute to sustainable growth of the personalized medicines market in the medium to long term.

Personalized Medicine Market: Key Players

Some key players in this market are Roche Holding AG, Astra Zeneca PLC, Vertex Pharmaceuticals Inc., Qiagen Inc., BD (Becton Dickinson & Co., Merck & Co. Inc., Pfizer Inc., American Association for Cancer Research, Siemens Healthcare Diagnostics, Inc. among others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Regional analysis includes

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

APEJ (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE -All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Follow this link:
Personalized Medicine Market - Global Industry Analysis, Size ...

November 14 15, 2018 Harvard Medical School, Boston, MA

We need to make the transition to a predict, prevent and protect health system.

Joshua Ofman, M.D., M.S.H.S.Senior Vice President, Global Value, Access and Policy, Amgen

*** Speakers will be added to the schedule on a rolling basis as they are confirmed. ***

7:00 a.m.

Registration and Continental Breakfast

Joseph B. Martin Conference Center at Harvard Medical School77 Avenue Louis Pasteur, Boston, MA 02115

8:00 a.m.

Opening Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

8:10 a.m.

Setting the Stage: Exploring the Promise of Personalized Medicine A Keynote Address

SPEAKER | Elizabeth Nabel, M.D., President, Brigham and Womens Hospital

8:55 a.m.

Shifting Systems: Identifying the Common Challenges and Notable Achievements of Government Efforts to Advance Personalized Medicine

Government executives have an enormous influence over the direction of health systems and can therefore play a role in developing personalized medicine but they need to know what works and what doesnt if their respective efforts to promote personalized medicine are going to succeed. With that in mind, government representatives from around the globe will discuss the competitive advantages various countries have in personalized medicine and explore the common challenges and notable achievements of government initiatives to advance the field during this panel discussion.

MODERATOR | Antonio L. Andreu, M.D., Ph.D., Scientific Director, EATRIS European Infrastructure for Translational Medicine

Ora Dar, Ph.D., Senior Expert, Medical Sciences, consultant to the Israel Innovation Authority

Tom Fowler, Ph.D., Deputy Chief Scientist, Genomics England

Marc LePage, President, CEO, Genome Canada

Liisa-Maria Voipio-Pulkki, M.D., Ph.D., Director General, Chief Medical Officer, Ministry of Social Affairs and Health, Finland

10:10 a.m.

Networking Break

Light refreshments provided.

10:40 a.m.

Evaluating Patients Priorities: Understanding Perspectives on Personalized Medicine A Fireside Chat

MODERATOR | Susan McClure, Founder, Publisher, Genome magazine; Board Member, Personalized Medicine Coalition

Emily Kramer-Golinkoff, Co-Founder, Emilys Entourage, cystic fibrosis patient

Bryce Olson, Global Marketing Director, Health and Life Sciences Group, Intel Corporation; stage IV prostate cancer patient

11:10 a.m.

Automating Actionable: How Artificial Intelligence May Chart a Course for Personalized Medicine

Artificial intelligence may help inform personalized medicine in the future by perceiving which genes, proteins and other biological characteristics contribute to human disease. During this session, a diverse panel will discuss how artificial intelligence may accelerate drug development, improve clinical decision support and drive patient outcomes and what that might mean for the future of health care.

MODERATOR | Colin Hill, Chairman, CEO, Co-Founder, GNS Healthcare

Tom Miller, Managing Partner, GreyBird Ventures LLC

Gregg Talbert, Ph.D., Global Head of Digital and Personalized Health Care Partnering, Roche

Darrell M. West, Ph.D., Vice President of Governance Studies and Director of Center for Technology Innovation, Douglas Dillon Chair in Governance Studies, The Brookings Institution

1:40 p.m.

The Lay of the Lab: Exploring the State of the Clinical Laboratory Testing Industry A Keynote Address

SPEAKER | David King, J.D., Chairman, CEO, LabCorp

2:25 p.m.

The Diagnostics Discussion: Evaluating the Extent to Which the Regulatory and Reimbursement Environment for Diagnostic Tests May Help or Hinder Personalized Medicine

The U.S. Food and Drug Administration and the U.S. Centers for Medicare and Medicaid Services have been working for over a decade to develop regulatory and reimbursement pathways that promote the development of innovative diagnostic tests. Many observers, however, believe the current regulatory and reimbursement landscape still limits the field. This panel of business leaders will discuss the extent to which the existing frameworks and proposed policies may help or hinder personalized medicine.

MODERATOR | Joseph V. Ferrara, CEO, Boston Healthcare Associates

Michael Doherty, Senior Vice President, Head of Product Development, Head of Research & Development, Foundation Medicine

Julie Khani, President, American Clinical Laboratory Association

Kimberly Popovits, Chairman of the Board, CEO, President, Genomic Health

Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific

3:25 p.m.

Networking Break

Light refreshments provided.

Sponsored By

3:55 p.m.

Examining Policies: Exploring How Emerging U.S. Regulatory Approaches May Help Facilitate Personalized Care Regimens

The U.S. Food and Drug Administration (FDA) remains firmly committed to regulatory strategies designed to advance personalized medicine. During this wide-ranging fireside chat, two senior leaders from government and industry will discuss the agencys latest actions impacting the oversight of personalized medicine products and services. The discussion will cover topics including but not limited to next-generation sequencing, diagnostic test regulation, digital health, and real-world evidence.

MODERATOR | Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition

Jesse Berlin, Sc.D., Vice President and Global Head of Epidemiology, Johnson and Johnson

Lauren Silvis, J.D., Chief of Staff, Immediate Office of the Commissioner, FDA

4:55 p.m.

Engaging Everyone: Leveraging Diversity and Facilitating Equitable Access to Personalized Care

Advancing a medical paradigm that focuses on the unique characteristics of each patient will require, by definition, that patients from diverse backgrounds participate in the medical studies that advance our understanding of disease. Also critical is the need to ensure that those patients have access to personalized care informed by those studies. During this session, four panelists will discuss the effort to ensure that all patient populations benefit equally from personalized medicine.

MODERATOR | Donna R. Cryer, J.D., President, CEO, Global Liver Institute

Vence L. Bonham, Jr., J.D., Senior Advisor, Director on Genomics and Health Disparities, U.S. National Human Genome Research Institute

Alex J. Carlisle, Ph.D., Chairman, CEO, National Alliance Against Disparities in Patient Health

Adolph P. Falcn, Executive Vice President, National Alliance for Hispanic Health

Edward Tepporn, Executive Vice President, Asian & Pacific Islander American Health Forum

5:55 p.m.

Closing Remarks

SPEAKER | Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health

6:10 p.m.

Departure for the Museum of Fine Arts, Boston

6:30 p.m.

Welcome Reception at the Museum of Fine Arts, Boston

Avenue of the Arts465 Huntington AvenueBoston, MA 02115

Sponsored by

We will convene for cocktails and hors doeuvres at the Boston Museum of Fine Arts immediately after the first day of conference programming. The museum is in walking distance from the Conference Center.

Sponsored by

6:05 p.m.

Sponsored by

The successful implementation of [personalized medicine] will depend on the embrace of [its] principles in the business community.

Raju Kucherlapati, Ph.D.Paul C. Cabot Professor of Genetics, Harvard Medical School

*** Speakers will be added to the schedule on a rolling basis as they are confirmed. ***

7:00 a.m.

Registration and Continental Breakfast

Joseph B. Martin Conference Center at Harvard Medical School77 Avenue Louis Pasteur, Boston, MA 02115

8:00 a.m.

Opening Remarks

SPEAKER | Stephen L. Eck, M.D., Ph.D., Chief Medical Officer, Immatics U.S. Inc; Board Chair, Personalized Medicine Coalition

8:10 a.m.

Pioneering Precision: Inside the Pharmaceutical Industrys Push Toward Personalized Medicine A Fireside Chat

MODERATOR | Meg Tirrell, Reporter, CNBC

Daniel ODay, CEO, Roche Pharmaceuticals

8:55 a.m.

Considering Costs: Evaluating Emerging Pharmaceutical and Insurance Industry Business Models in Personalized Medicine

The pharmaceutical industry is deeply invested in commercializing personalized therapies that must recoup fixed development costs from smaller patient populations covered by health insurance companies that are increasingly concerned about rising health care costs. In that context, this diverse panel will explore the viability of the business model for developing and paying for personalized medicines, tackling issues related to costs, prices, and access.

MODERATOR | Meg Tirrell, Reporter, CNBC

Read more:
2018 Schedule 15th Annual Personalized Medicine Conference

As your doctor, I practice medicine in a different way than you may be used to. As medical practices get larger and suffer under increasing insurance restraints, many have come to lack something very importantpersonal attention. Due to sagging reimbursements by insurance companies and higher operating costs, many practices are forced to see many patients every day. I want to care for you on a more personal level.

By keeping my practice small, I can focus first on who you are as a person instead of your illness or symptoms. And youll see only me not a nurse practitioner or other doctorsso you get the attention you deserve in a caring, warm environment.

My practice is based on a partial concierge or membership medicine model. This allows me to limit the number of patients I see and provide the personalized, comprehensive primary care you cant find in most doctors offices.

If you choose to become a member, for an affordable annual fee you can access same- or next-day unrushed appointments that allow me to address all of your questions and concerns. And because youll have ongoing direct communication with me, sometimes you can avoid an appointment altogether, or even a trip to the Emergency Department.

Not ready to become a member yet? Thats okay. Im still happy to see youjust understand that many of these special service benefits are for members only.

My smaller practice allows me to focus on more than treating problems, but also teaching wellness and prevention with the goal of living a long and healthy life free from disease. See our services.

Our healthcare system is filled with plenty of challenges, but having a doctor who can spend enough time with you shouldnt be one of them. I look forward to providing you the attentive, personalized care you have always hoped to find.

Do you have questions? Please call us at (910) 762-4488. Our Patient Membership Coordinator / Office Manager Linda will be happy to help you.

~ Dr. Steve LiederbachBoard Certified, Internal Medicine

Read more:
Wilmington Adult Medicine Personalized Medicine Membership ...

Sessions and Tracks

Theme:

About Conference:

The 11th International conference onPredictive Preventive and PersonalizedMedicine & Molecular Diagnostics will be held on October 25-26, 2019 at Vancouver, Canada.whichcomprises 18Sessions/Tracksto outline the theme of the conference organized by Conference series LLC LTD. The main aim of the conference is to highlight the achievements and innovations in the various fields of Personalized Medicine across the globe.

Tracks: 1 Paths of Biomarkers

In medication, a biomarker and sub-atomic markers are the quantifiable pointer of the seriousness or vicinity of some infection state. All the more by and large a biomarker is anything that can be utilized as a marker of a specific ailment state or some other physiological condition of a living being Drug-Diagnostic Co-Development. In the present period of stratified solution and biomarker-driven treatments, the centre has moved from forecasts taking into account the conventional anatomic arranging frameworks to direct the decision of treatment for an individual patient to a coordinated methodology utilizing the hereditary cosmetics of the tumour and the genotype of the patient. Genomics and other innovations have to a great extent added to the recognizable proof and the improvement of biomarkers such as Stratification biomarkers in customized pharmaceutical.

Track 2: Clinical Case Reports: Genetics

Customized solution depends on interspecies contrasts. It is proverbial that little contrasts in hereditary make-up can bring about emotional contrasts because of medications or ailment and societal effect of customized pharmaceutical. To express this in more broad terms in any given complex framework, little changes in beginning conditions can bring about drastically diverse results. In spite of human variability and interspecies variety in different species, nonhuman species are still the essential model for finding out information for personalized solution wellbeing change in Human.

Track 3: Life Style Medicine

Life Medicine (LM) is the utilization of way of life mediations in the treatment and administration of infection. LM is turning into the favoured methodology for the counteractive action as well as the treatment of most perpetual sicknesses, including Type-2 Diabetes, Coronary Heart Disease, Hypertension, Obesity, Insulin Resistance Syndrome, Osteoporosis, malignancy prevention. Likewise incorporate Aerobic and Resistance practices for patients with diabetes, Sleep and infection counteractive action, intrinsic inspiration and wellbeing conduct adherence.

Track 4: Preventive Medicine

Preventive Medicine is honed by all doctors to keep their patients sound. It is additionally an exceptional medicinal claim to fame perceived by the American Board of Medical Specialties (ABMS). Preventive Medicine concentrates on the wellbeing of people, groups, and characterized populaces. It is likewise utilized for the treatment for stoutness, visual impairment. The Epidemiology Division applies research strategies to comprehend the examples and reasons for wellbeing and ailment in the populace and to make an interpretation of this learning into projects intended to avert malady. The division has a long history of inclusion in NIH-supported multi-site, longitudinal partner studies, and its personnel manage numerous specialist started, NIH-supported exploration ventures and trials.

Track 5: Personalized Medicine & its Innovation

Personalized Medicine is a developing routine of medication that uses an individual's hereditary profile to guide choices made with respect to the counteractive action, determination, and treatment of ailment. Information of a patient's hereditary profile can offer specialists some assistance with selecting the best possible prescription or treatment and manage it utilizing the correct measurement or regimen. Utilized for the treatment as Personalized growth solution, Diabetes-related sickness: hazard appraisal and administration, Personalized pharmaceutical: New procedures and monetary ramifications, Implications of customized prescription in treatment of HIV, Applications of customized drug in uncommon illnesses, Translational Medicine.

Track 6: Advances in Molecular Diagnostics

Personalized Medicine is a developing routine of medication that uses an individual's hereditary profile to guide choices made with respect to the counteractive action, determination, and treatment of ailment. Information of a patient's hereditary profile can offer specialists some assistance with selecting the best possible prescription or treatment and manage it utilizing the correct measurement or regimen. Utilized for the treatment as Personalized growth solution, Diabetes-related sickness: hazard appraisal and administration, Personalized pharmaceutical: New procedures and monetary ramifications, Implications of customized prescription in treatment of HIV, Applications of customized drug in uncommon illnesses, Translational Medicine.

Track 7: Market Strategies & Challenges In Personalised Medicine

P4 Medicine is an arrangement to profoundly enhance the nature of human life by means of biotechnology. P4 Medicine is a term authored by scholar Leroy Hood, and is another way to say "Predictive, Preventive, Personalized Medicine, and Molecular Medicine." The reason of P4 Medicine is that, throughout the following 20 years, restorative practice will be altered by biotechnology, to deal with a man's wellbeing, rather than deal with a patient's infection. Inner solution or general medication (in Commonwealth countries) is the medicinal claim to fame managing the avoidance, determination, and treatment of grown-up maladies. Crisis solution is a medicinal claim to fame including watch over grown-up and paediatric patients with intense sicknesses or wounds that require quick therapeutic consideration.

Track 9: Novelty in Personalised Medicine

Personalized Medicine is a developing routine of prescription that uses an individual's hereditary profile to guide choices made with respect to the counteractive action, analysis, and treatment of malady. Learning of a patient's hereditary profile can offer specialists some assistance with selecting the correct prescription or treatment and control it utilizing the best possible measurements or regimen. Utilized for the treatment as Personalized malignancy pharmaceutical, Diabetes-related sickness: hazard evaluation and administration, Personalized drug: New procedures and monetary ramifications, Implications of customized medication in treatment of HIV, Applications of customized prescription in uncommon infections, Translational Medicine.

Track 10: Genomics & Personalized Medicine

Genomics is a control in hereditary qualities that applies Recombinant DNA, DNA sequencing techniques, and bioinformatics to grouping, amass, and break down the capacity and structure of genomes. Propels in genomics have set off an insurgency in disclosure based examination to see even the most complex organic frameworks, for example, the mind. The field incorporates endeavours to decide the whole DNA grouping and human genome variation of life forms and fine-scale hereditary mapping. The field additionally incorporates investigations of intragenomic marvels, for example, heterosis, epistasis, pleiotropy and different associations in the middle of loci and all within the genome and met genomics.

Track 11: Genetics of Ebola Outbreak

Arrangement investigation of Ebola infection Genome is the second through the 6th qualities of the Ebola infection (EBO) genome demonstrates that it is sorted out also to rhabdoviruses and paramyxoviruses and is for all intents and purposes the same as Marburg infection (MBG). Researchers utilized genomic sequencing advancements to recognize the starting point and track transmission of the Ebola infection in the ebb and flow flare-up in Africa.

Track 12: Approaches To Stem Cells

Personalized Medicine can be utilized to find out around a man's hereditary cosmetics and to disentangle the science of their tumour. Utilizing this data, specialists want to recognize anticipation, screening, and treatment techniques that might be more successful and cause less symptoms than would be normal with standard medicines. By performing more hereditary tests and examination, specialists might alter treatment to every patient's needs. Making a customized malignancy screening and treatment arrangement incorporates: Determining the odds that a man will create growth and selecting screening techniques to bring down the danger, Matching patients with medications that will probably be compelling and cause less reactions, Predicting the danger of repeat (return of Cancer)

Track 13: Nanotechnology: Future of Personalised Medicine

Nanotechnology ("nanotech") is the control of matter on a nuclear, atomic, and supramolecular scale. The soonest, across the board portrayal of nanotechnology alluded to the specific mechanical objective of accurately controlling particles and atoms for creation of macro scale items, likewise now alluded to as sub-atomic nanotechnology. Uses of pharmaceutical Nano tools, Cell based treatment Molecular systems are the strategies and instrument in Nano innovation and biotechnology.

Track 14: Personalized Drug Therapy

The personalizeddrug is a field of medication that involves foreseeing the likelihood of malady and establishing preventive measures keeping in mind the end goal to either keep the ailment by and large or altogether abatement its effect upon the patient, (for example, by avoiding mortality or constraining dreariness). Methods and measures incorporate New-born screening,Diagnostic testing, Medical bioinformatics, Prenatal testing, Carrier testing, Preconception testing. Infant screening is a general wellbeing program intended to screen babies not long after conception for a rundown of conditions that are treatable, however not clinically clear in the infant period. Pre-birth testing: Prenatal testing is utilized to search for sicknesses and conditions in a hatchling or developing life before it is conceived. This kind of testing is offered for couples who have an expanded danger of having a child with a hereditary or chromosomal issue.

Track 15: Personalized Oncology

The era of personalized oncology medicine has the potential to fulfil the promise of delivering the right dose for the right indication to the right patient at the right time. Imagine your oncologist knowing before he makes a treatment decision how well your cancer may respond to a particular therapy. Tools that enable a more informed treatment decision do exist and may help individualize your cancer care. It is very important for oncologists to keep updated of the latest advancements in oncology as changes in management of cancer are quite common. All fit patients whose cancer progresses and no standard of care treatment options are available should be enrolled in a clinical trial. Personalized medicine is used to learn about a persons genetic makeup and how their tumor grows. Using this data, doctors hope to find prevention, screening, and treatment strategies that may be more effective. They also want to find ones that cause fewer side effects than the standard treatments. By performing more genetic tests, doctors may customize treatment to each patients needs.

Track 16: Immunology Infectious Disease

Clinical immunology is the study of diseases caused by disorders of the immune system. It also involves diseases of other systems, where immune reactions play a part in the pathology and clinical features. Many components of the immune system are actually cellular in nature and not associated with any specific organ but rather are embedded or circulating in various tissues located throughout the body. Immunotherapy is a new class of cancer treatment that works to harness the innate powers of the immune system to fight cancer. Because of the immune system's unique properties, these therapies may hold greater potential than current treatment approaches to fight cancer more powerfully, to offer longer-term protection against the disease, to come with fewer side effects, and to benefit more patients with more cancer types. Scientists believe that for most people, Alzheimer's disease results from a combination of genetic, lifestyle and environmental factors that affect the brain over time. In Parkinsons disease, cells that produce dopamine start to die. Dopamine is a chemical that helps you move normally. There is no known direct cause of Parkinsons. One theory is that it may be hereditary. Other theories say exposure to pesticides and living in rural communities may cause it.

Track 17: Cardiology and Vascular Medicine

The objective of the Cardiac Research is to quicken interpretation of promising new crucial examination revelations for the treatment of heart disappointment and arrhythmias through very much composed clinical trials that exhibit viability and security. Vascular Medicine envelops a wide range of different disease states. As the field of vascular Medicine develops, the extent of illnesses being dealt with changes. Cardiovascular renovating alludes to the adjustments in size, shape, structure and physiology of the heart after damage to the myocardium. The harm is normally because of intense myocardial dead tissue. To portray the expansion in lipoprotein interpretation by hypothyroidism, adipocytes were readied from control and hypothyroid rats. While LPL combination was higher in hypothyroid adipocytes, with no adjustment in mRNA levels, there was no expansion in hormone-touchy lipase (HSL) blend.

Read more here:
Medicine conferences 2019: Personalized | Predictive ...

His groundbreaking work has changed the very ways we consider our health and examine disease. (President Barack Obama)

The future of customized medicine is in your DNA; dont wait until you are sick to learn why. (Dr. Mehmet Oz, author of You: The Owner's Manual)

With fluid prose and compelling narratives, Francis Collins makes modern medical science vivid and accessible. This book sets out hope without hype, and will enrich the mind and uplift the heart. (Jerome Groopman, M.D., Recanati Professor, Harvard Medical School, Author of How Doctors Think)

Mans knowledge of man is undergoing the greatest revolution since Leonardo, and Francis Collins is at the leading edge of it. I am a better doctor today because Dr. Collins was my genetics professor in medical school, and now, the world gets to benefit from his wisdom by reading The Language of Life. (Dr. Sanjay Gupta, Neurosurgeon at Emory University and Chief Medical Correspondent for CNN)

Link:
The Language of Life: DNA and the Revolution in ...

The 14th Annual Personalized Medicine Conference: Preparing for the New Possible will convene the worlds leading researchers, investors, industry executives, policy experts, payers, clinicians, and patient advocates to define the landscape and outlook for personalized medicine in science, business, and policy. Participants will examine the infrastructure and business strategies necessary to overcome scientific obstacles, optimize public policies, and change embedded medical norms as we seek to accelerate investment in and adoption of personalized medicine.

Featured Speakers

Amy P. Abernethy, M.D., Ph.D.

Chief Medical Officer, Chief Scientific Officer

Flatiron Health

Donna R. Cryer, J.D.

President, CEO

Global Liver Institute

Luba Greenwood, J.D.

Strategic Business Development and Corporate Ventures

Verily, an Alphabet Company

David King, J.D.

Chairman, CEO

LabCorp

Daniel P. ODay, M.B.A.

Chief Executive Officer

Roche Pharmaceuticals

Ellen V. Sigal, Ph.D.

Chairperson, Founder

Friends of Cancer Research

Ralph Snyderman, M.D.

James B. Duke Professor of Medicine

Duke University

Keith Stewart, M.B., Ch.B.

Carlson and Nelson Endowed Director, Center for Individualized Medicine

Mayo Clinic

Liisa-Maria Voipio-Pulkki, M.D., Ph.D.

Director General, Chief Medical Officer, Ministry of Social Affairs and Health

Finland

View full List of Speakers

Continued here:
14th Annual Personalized Medicine Conference November 14 ...

Personalized Adult Primary and Preventive Medicine in Denver, ColoradoFloyd Russak, MD with Katie Bunt, MA(left) and Kimberly Boonstra ( right)Personalized MedicineAbout My Practice

I see patients through my personalized medicine membership practice. This personalized approach to primary care health delivery will change how you perceive your health health and engage with me as your doctor.

Read More

My Clinical Assistant, Katie Bunt (above left) and my Executive Assistant, Renee Collishaw (above right) are at your service. They are committed to exceeding your expectations and helping me help you optimize your health.

As a personalized care program member, you'll enjoy the finest in preventive health coupled with breakthrough diagnostics and treatments.

Read More

You're going to love the convenience of our on-site diagnostic screening and laboratory services! No more wasted time and energy running around town from place to place to meet your healthcare needs.

Read More

Dr. Russak is committed to providing all of his personalized membership patients with the finest in preventive care, breakthrough diagnostics and treatments, rapid access appointments and telemedicine.

He believes that appointments should start on time and last as long as necessary, and that you should have access to a dedicated physician invested in your well-being 24 hours a day, 365 days a year.

At Russak Personalized Medicine, our priority is to deliver quality care to informed patients in a comfortable and convenient setting.

Quality Care

When you have needs for medical care, you need to turn to a doctor who listens and responds an experienced doctor who knows the field and can effectively diagnose and treat your needs a friendly physician who counsels you on the best ways to maintain and improve your health. Our physician(s) meet all these criteria. Plus, you benefit from a dedicated team of trained professionals who give you the individualized attention you deserve.

Informed Patients

Russak Personalized Medicinebelieves that informed patients are better prepared to make decisions regarding their health and well-being.

Comfortable, Convenient Setting

The best care in the world doesnt mean anything if you cant access it. At Russak Personalized Medicine, we strive to make our Greenwood Village office as efficient and convenient as possible. Included in these web pages is information aboutRussak Personalized Medicines office, including our Greenwood Village location, maps, directions, hours, insurance policies, and appointment scheduling. You can even email a request for an appointment right here! We hope you find this website useful and invite you to contact us with your questions at any time.

Read the original here:
Russak Personalized Medicine - Primary Care Physician in ...

Just as every person is unique, so is every cancer. At the Knight Cancer Institute, were dedicated to finding what makes each cancer unique and providing individually tailored and targeted treatments.

Our pioneering work in personalized medicine ultimately led to the discovery of one of the worlds first targeted cancer drugs, Gleevec, by Dr. Brian Druker at the OHSU Knight Cancer Institute. Gleevec truly revolutionized the way cancer is treated and works by zeroing in and eliminating specific cancer-causing cells, while avoiding serious damage to other non-cancerous ones. This major turning point in the treatment of cancer has led us to expand our focus on delivering personalized care by recruiting the very best and most experienced clinicians and researchers from across the country. But we wont stop there! Through our efforts in cancer research, diagnostics, drug development and treatments, we continue to lead the way in the field of personalized care.

Dr. Druker has stated that Our goal going forward is to advance science so that someday there will be a targeted therapy to shut down every form of cancer. At the OHSU Knight Cancer Institute, each of us believes in a world without cancer and has a mission to end this disease in our lifetime.

Asleadersinthefieldofpersonalizedmedicine,weare investing in:

At the Knight Cancer Institute our physicians, pathologists, researchers and other member of the team work together to bring each patient the best personalized care available. For us it truly is:

See more here:
Personalized Cancer Medicine | Knight Cancer Institute | OHSU

Sunday2:00 pm - 8:00 pm

Arrival and Check-in

Dinner

Introductory Comments by GRC Site Staff / Welcome from the GRC Chair

Discussion Leader: Chih-Ming Ho (University of California, Los Angeles, USA)

Introduction by Discussion Leader

Dean Ho (BIGHEART, National University of Singapore, Singapore)

Discussion

Edward Kai-Hua Chow (Cancer Science Institute of Singapore, National University of Singapore, Singapore)

Discussion

Bin Tean Teh (National Cancer Centre Singapore, Singapore)

Discussion

General Discussion

Breakfast

Discussion Leader: Mien-Chie Hung (University of Texas MD Anderson Cancer Center, USA)

Introduction by Discussion Leader

Wei Zhang (Comprehensive Cancer Center, Wake Forest University, USA)

Discussion

Group Photo / Coffee Break

Chuan He (University of Chicago, USA)

Discussion

Jindan Yu (Northwestern University, USA)

Discussion

General Discussion

Lunch

Free Time

Poster Session

Dinner

Discussion Leader: Rita Yen-Hua Huang (Taipei Medical University, Taiwan)

Introduction by Discussion Leader

Ye-Guang Chen (Tsinghua University, China)

Discussion

Bradley Cairns (University of Utah, USA)

Discussion

General Discussion

Breakfast

Discussion Leader: Wei Jia (University of Hawaii Cancer Center, USA)

Introduction by Discussion Leader

Neal Rosen (Memorial Sloan Kettering Cancer Center, USA)

Discussion

Coffee Break

Van-Dang Chi (Ludwig Cancer Research, USA)

Discussion

Shengfang Jin (Agios Pharmaceuticals Inc, USA)

Discussion

General Discussion

Lunch

Poster Session

Discussion Leader: Tony S.K. Mok (Chinese University of Hong Kong, Hong Kong SAR China)

Introduction by Discussion Leader

Patrycja Nowak-Sliwinska (University of Geneva, Switzerland)

Discussion

Hong Wu (School of Life Sciences, Peking University, China)

Discussion

Jonathan Keats (Translational Genomics Research Institute (TGen) / City of Hope, USA)

Discussion

General Discussion

Dinner

Breakfast

Discussion Leader: Priscilla Kelly (Science, AAAS, USA)

Introduction by Discussion Leader

Pui-Yan Kwok (Institute of Biomedical Sciences, Academia Sinica, Taiwan)

Discussion

Sridhar Mani (Albert Einstein College of Medicine, USA)

Discussion

Coffee Break

Christiane Querfeld (Cutaneous Lymphoma Program, City of Hope, USA)

Discussion

Irene O.L. Ng (The University of Hong Kong, Hong Kong SAR China)

Discussion

General Discussion

Lunch

Free Time

Poster Session

Dinner

Business MeetingNominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair

Discussion Leader: Richard Weinshilboum (Mayo Clinic, USA)

Introduction by Discussion Leader

James Lee (University of Pittsburgh School of Medicine, USA)

Discussion

Steven Offer (Mayo Clinic, USA)

Discussion

Liewei Wang (Mayo Clinic, USA)

Discussion

General Discussion

Breakfast

Discussion Leader: Chien-Tsun Kuan (Development Center for Biotechnology, Taiwan)

Introduction by Discussion Leader

Arjan Griffioen (VU University Medical Center, The Netherlands)

Discussion

John Williams (Beckman Research Institute, City of Hope, USA)

Discussion

Coffee Break

Xianting Ding (Institute for Personalized Medicine, Shanghai Jiao Tong University, China)

Discussion

Ali Zarrinpar (Division of Transplantation and Hepatobiliary Surgery, University of Florida College of Medicine, USA)

Discussion

General Discussion

Lunch

Free Time

Read more here:
2018 Personalized Medicine Conference GRC

Personalized medicine relies on tests to help determine an individuals response to certain medications.

Personalized medicine takes into account your unique genetic makeup. Unlike "genetic medicine," which is directed at such inherited diseases as sickle cell anemia, personalized medicine can help your doctor tailor treatment for conditions such as heart disease and deep vein thrombosis. This enables him/her to focus on prevention, detection and early intervention.

Your genetic makeup also affects which medicines work best for youand how you respond to them. Your doctor can prescribe targeted treatment based on both:

We offer two such tests, which represent the forefront of personalized medicine. They can determine your response to two of the most widely prescribed drugs.

Marketed as Coumadin and Jantoven, warfarin thins the blood to help prevent and treat deep vein thrombosis, stroke, heart attack, atrial fibrillation and other diseases of the arteries and veins. The right dosage is crucial. Too low a dose could increase the risk of a life-threatening blood clot. Too high a dose could increase bleeding risk. Plus, your response to a specific dose can vary widely. We offer the AccuType Warfarin test to help your physician determine the appropriate dosage based on your genetic information.

Marketed as Plavix, clopidogrel is another blood thinner. The AccuType CP test identifies if youre unlikely to respond well to the drug and therefore at increased risk for stroke or heart attack. It also identifies if youre likely to be overly sensitive to the drug and therefore at increased risk for bleeding episodes.

Personalized medicine, including these two laboratory tests, can help make possible:

The rest is here:
Health and Wellness : Personalized Medicine

It's time to accelerate medical progress.

Since its inception, The Jackson Laboratory has led the discovery of causes, treatments and cures for some of humankind's most devastating genetic diseases. Today, we are speeding the path of discovery from the laboratory bench to clinical care. We are combining the skills and knowledge of our scientists with our institutional strengths in disease modeling and bioinformatics, connecting genetics to genomics, and using our unparalleled knowledge of mouse models of disease to understand the human condition.

JAX research programs are leading efforts to improve human health worldwide.

Addiction is a chronic illness, with genetic, environmental and social aspects. JAX researchers are at the forefront of understanding the genetic factors involved in individuals vulnerability to addiction.

JAX researchers are using genomic technologies and specialized mouse models to decipher the changes that occur as a consequence of aging in order to extend our health span, delay age-related health issues, repair damaged organs and improve our quality of life.

Using genomic technologies and specialized mouse models to develop preventative therapies, JAX scientists aim to stop Alzheimers before it starts.

Driven by the desire to eradicate cancer, we are leading the future of cancer treatments by combining computational expertise with our unparalleled knowledge of mouse genetics.

JAX researchers investigate the processes that lead to failure to produce insulin in type 1 diabetes and loss of insulin production in type 2 diabetes.

JAX researchers are exploring the effect on health and disease of the microorganisms that outnumber human cells 10 to 1.

About 80 percent of rare diseases are genetic in origin, about half affect children, many are fatal, and very few have cures.

More here:
Personalized Medicine | The Jackson Laboratory

Immuno-oncology (I-O) relates to the recruitment of ones own immune system for the treatment and eradication of cancer. Remarkable clinical results with immuno-oncology treatments within the past 5 years, in particular with immune checkpoint inhibitor drugs, have catapulted the field onto center stage for consideration by patients, clinicians, academic investigators as well as pharmaceutical and biotech companies.

The I-O premise is relatively straightforward to unleash the killing potential due to the exquisite specificity of a patients T lymphocytes (predominantly CD8 T cells) to target and eliminate cancer cells throughout the body. Administration of immune checkpoint inhibitor drugs, such as monoclonal antibodies (e.g., Keytruda, Opdivo, Tecentriq) that interfere with the T cell immune restraints imposed by PD-1 : PD-L1 receptor interactions have dramatically realized the potential to yield rapid and durable clinical responses in those patients whose T cells have already been trained, yet silenced, to eliminate the tumors. These drugs, while highly effective for patients with different cancers (e.g., melanoma, lung and bladder cancers), are limited to benefit those 20-30% of patients whose immune system shows evidence of pre-existing cancer recognition.

On closer scrutiny of the T cell immune responses in patients that benefit from monotherapy treatment with immune checkpoint inhibitordrugs, significant evidence has been generated that the patients CD8 T cells likely target protein mutations (antigens) unique to the tumor (neo-antigens). As shown in the figures below, patients whose tumors harbored a greater collection of unique mutations (high nonsynonymous burden; neo-antigen burden) were significantly more likely to benefit clinically from immune checkpoint anti-PD-1 drug monotherapy. This means that the patients already had a collection of CD8 T cells with the ability to recognize peptides derived from these neo-antigens presented to the immune system on the HLA receptors on tumors (neo-epitopes). Since these neo-epitopes are only displayed on the surface of tumor cells, patient T cells that target neo-epitopes should only kill tumor cells. Unleashing the patients neo-epitope specific T cells is, therefore, likely responsible for the rapid and durable clinical benefits seen in some patients upon administration of immune checkpoint inhibitor drugs.

The next wave in immuno-oncology success will depend on initiating highly specific T cell immune recognition of cancers. Based on the current evidence, unleashing a tsunami of T cells that recognize and kill cancer cells displaying patient-specific mutations (neo-epitopes) holds great potential to significantly increase the number of cancer patients that will benefit from I-O therapies.

PACT Pharma is dedicated to synthesizing a tsunami of neo-epitope targeted T cells and producing a personalized adoptive cell therapy designed to benefit each individual cancer patient (as outlined in the diagram below). The neo-epitope targeting is engineered into the patients own T cells (autologous T cells) for programming to seek out, infiltrate into the tumor and kill the tumor cells displaying the unique neo-epitopes. In essence, PACT Pharma is engineering next generation synthetic tumor-infiltrating lymphocytes (synthetic TILs), tailored for each patients cancer with highly efficient turnaround in manufacturing from tumor biopsy to re-infusion of autologous synthetic TILs back into the patient.

Our proprietary approach, the imPACTTM isolation technology, utilizes a highly sensitive nanoparticle and microfluidic engineering system and fabricated chips to identify and to isolate very rare T cells in patients that already recognize the cancer neo-epitopes. The figure below reveals that these T cells can be interrogated for their specificity of neo-epitope recognition. Using a barcode system on the nanoparticle, together with a series of three different fluor-bound DNA sequences, the neo-epitope specificity of each CD8 T cell trapped in the chip is translated (e.g. T cell #3 yielded a signal of yellow-red-green, which translates to neo-epitope #12 in the table below).

Following imPACTTMisolation, our machine learning algorithms define the most relevant neo-epitope (NeoE) specific CD8 T cells for therapeutic benefit, from which we extract the T cell receptor (TCR) sequences for PACT TCR-T product development. Using (non-viral) precision genome engineering, the NeoE-targeted TCR sequences replace the endogenous TCR of fresh CD8 and CD4 T cells collected from that same patients peripheral blood (autologous NeoE TCR engineered into autologous fresh T cells) followed by minimal expansion in preparation for re-infusion into the patient. These patient-specific TCR-T cells are formulated to immediately kill all neoantigen-expressing tumors, together with a deep reservoir of ready-to-go TCR-T cells for long term persistence and capable of rapid expansion to prevent future cancer recurrence.

In summary, PACT Pharma is engineering autologous synthetic TILs, which, when administered into the patient, are designed as a tsunami of tumor-specific T cells capable of rapid elimination of cancer throughout the body for durable clinical benefit. This is the promise of next-generation immuno-oncology: to unleash the patients immune system to eradicate cancer

Continued here:
Personalized Medicine | PACT Pharma, Inc.

Product Options:"Ellie's idea of testing your blood to know how to optimize your own nutrition--not anyone's else's--just makes sense. And it works." Vicki Nassif, DDSYFH uses its 40 year data base to compute your optimum rangeand determine your risk factors, NOT justtell you that yourblood test scores are in the lab normal range.Early detection of disease (found by YFH's database) is the key to protecting your health.

"Ellie shows that individuals have distinctive Personal Normal scores that are in a much more narrow range than the laboratory's "normals". This tool for early detection of disease is the key to preventing illness." Dan C. Dantini, MD

YFH provides a blood test kit with: every tube labeledfor accuracy, shipping materials, doctor order, draw siteset up, and your blood results electronically fed fromthe exact equipment YFH stipulates. (Most blood test companies JUST provide the doctor's order.) Also, your blood test results are triple checked and scores can always be compared because YFH controls the test protocol and uses the best equipment each time. Extra serum is collected andfrozen so you can be notified if additional tests are neededto clarify a suspicious score.FREE group telephone test explanations are held regularly.In addition, YFH has a program for international orders (please call or email for details).YFH's trained customer service representatives listen and help you choose thebest group of testsfor your budget. HealthPrint+results include a 200 page guide and YFH's power foods list which includes food and nutritional suggestions customized to your scores. However, we do not sell supplements so there is no conflict of interest. Why not take control of your health today!

Read the original post:
Your Future Health

At the Center for Personalized Medicine we specialize in customized treatment plans for each patient. We are dedicated to help you achieve your wellness objectives.

We understand the importance of your wellness. To achieve your wellness objectives, you have come to expect the highest levels of service and patient care. As a result, we continuously commit ourselves to meeting and exceeding your expectations. To us, providing a total healthcare experience means dedicated and friendly staff, flexible and convenient hours, and the highest quality care available.

Services Offered

At the Center for Personalized Medicine we specialize in prescription natural hormone replacement for both women and men. We can also customize a vitamin program for you. Your nutritional needs are as unique to you as your fingerprint.

At the Center for Personalized Medicine we can also help your memory stay sharp, help your skin stay more youthful, and show you safe and simple ways to increase your growth hormone level. We also have nurses and nutritionists who will meet with you to develop your own individualized weight management program to help you achieve maximum weight loss and keep the weight off.

Have our doctors show you how to lower cholesterol without a prescription. We help cancer patients with nutritional support. If you have diabetes, let us show you new treatment options. In short, at the Center for Personalized Medicine we will take a functional medicine approach to your health care needs.

Whether you want to maintain your current good health, or if you have a disease, we will look at how your body works and design a treatment plan for you and you only. We do not mask your symptoms with medications, we instead try to fix the cause of the problem and use medications only when necessary.

Read more from the original source:
Center for Personalized Medicine | Founder & Director ...

NIH-supported pharmacogenomics researchers are making steady progress towards understanding how genes influence drug responses. These findings will improve doctors ability to personalize treatment by predicting an individuals response to a drug regimen and pre-empting problems, promising a future of:

Instead of basing a starting dose only on characteristics like weight and age, doctors will use a patients genetic profile to determine the best drug and the optimal dose.

Pharmaceutical companies will be able to develop and market drugs for people with specific genetic profiles. Testing a drug candidate only in those likely to benefit from it could streamline clinical trials and speed the process of getting a drug to market.

Doctors will be able to prescribe the right dose of the right medicine the first time for everyone. This means that patients would receive medicines that are safer and more effective for them, speeding recovery, avoiding adverse reactions, and improving health care overall.

Contact: Office of Communications and Public Liaison National Institute of General Medical Sciences info@nigms.nih.gov 301-496-7301

http://www.nigms.nih.gov

See the rest here:
NIH Fact Sheets - From Genes to Personalized Medicines

CHICAGO, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data and University of California Davis Comprehensive Cancer Center are collaborating on a precision medicine partnership to advance clinical care with Next Generation Sequencing analysis, focused initially on patients diagnosed with hematological malignancies and pancreatic cancer.

As part of the collaboration, Tempus will do molecular sequencing and analysis for a group of patients at UC Davis Comprehensive Cancer Center. Utilizing machine learning and advanced bioinformatics, Tempus helps physicians analyze data sets in a search for potentially relevant patterns that can help guide treatment for patients who are unlikely to respond to conventional therapies or for whom no conventional therapies exist.

Technology has come a long way since researchers first mapped the genome more than 15 years ago and yet physicians and their patients have not widely benefited, said Eric Lefkofsky, Founder and CEO at Tempus. We are excited to bring the Tempus platform to physicians at the UC Davis Comprehensive Cancer Center who will now have access to technology and analytics that will support their efforts to deliver personalized treatment for each patient.

Tempus will work with a team of investigators led by Dr. Primo Lara, an esteemed investigator in clinical-translational research, who has chaired a number of cancer clinical trials from phase I to III.

Discovery is happening at a rapid pace and will continue to accelerate with access to data-driven tools designed to support work in the clinic, said Dr. Lara, Interim Director of the UC Davis Comprehensive Cancer Center. Working with Tempus is consistent with our commitment to providing our physicians with the tools and resources they need to best treat their patients.

The UC Davis Comprehensive Cancer Center is among the top-ranked national cancer programs for both research and patient care. It is one of 48 centers designated "comprehensive" by the National Cancer Institute.

About Tempus: Tempus is a technology company that is building the worlds largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com and follow us on Facebook (Tempus Labs) and Twitter (@TempusLabs).

About UC Davis Comprehensive Cancer CenterUC Davis Comprehensive Cancer Center is the only National Cancer Institute-designated center serving the Central Valley and inland Northern California, a region of more than 6 million people. Its specialists provide compassionate, comprehensive care for more than 10,000 adults and children every year, and access to more than 125 clinical trials at any given time. Its innovative research program engages more than 280 scientists at UC Davis, Lawrence Livermore National Laboratory and Jackson Laboratory (JAX West), whose scientific partnerships advance discovery of new tools to diagnose and treat cancer. Through the Cancer Care Network, UC Davis collaborates with hospitals and clinical centers throughout the Central Valley and Northern California to offer the latest cancer-care services to their communities. UC Davis community-based outreach and education programs address disparities in cancer outcomes across diverse populations. For more information, visit http://cancer.ucdavis.edu.

Read more here:
Tempus and University of California Davis Comprehensive Cancer ... - GlobeNewswire (press release)

On Thursday evenings beginning Oct. 12, UCSF Imagings world-renowned radiologists will participate in the UCSF Osher Center for Integrative Medicines Mini Medical School for the Public in a six-week series titled Personalized Medicine Powered by Precision Imaging. This informative course is open to the public. Attendees will have the opportunity to meet experts from UCSF Imaging, who are using and developing new and innovative precision imaging tools to enhance diagnosis, improve disease monitoring, and optimize treatment for individual patients.

In close partnership with subspecialty physicians from other UCSF departments, radiologists are now able to use these tools to pinpoint and better treat disorders such as prostate cancer, breast cancer and degenerative spine and joint disease at earlier stages. This series of lectures will explain how emerging technologiesincluding specific artificial intelligence platformswill rely upon imaging to dramatically improve accuracy, safety, and outcomes for patients in the very near future.

This course is co-chaired by William P. Dillon, MD, and Christopher P. Hess, MD, PhD, and there will be 17 faculty members participating in the lectures. The schedule is as follows:

To register for the full course, please visit osherminimed.ucsf.edu. To register for a single class, call (415) 476-5808. Each class will be held in the School of Nursing, Room N225, at 513 Parnassus, accessible through the Medical Science Building.

See the rest here:
Coming Soon: Osher Mini Medical School Series on Personalized Medicine Powered by Precision Imaging - UCSF Department of Radiology & Biomedical...

Calling the move "historic," the Food and Drug Administration announced approval August 30 for the first gene therapy in the U.S.

Its a gene therapy that hospital CIOs and IT shops, particularly those working on precision medicine initiatives, would be smart to watch since experts are already saying it is a fundamental turning point that holds promise to transform the practice of medicine.

Heres what healthcare executives and technologists should know.

Kymriah, the brand name under which Norvatis is marketing the drug tisagenlecleucel, offers a new treatment option that will first be explored for use in cases of acute lymphoblastic leukemia in kids and young adults.

The treatment, a genetically-modified autologous T-cell immunotherapy, was approved by FDA for use in patients aged 25 or younger who demonstrate certain characteristics of cancer.

Doses of Kymriah are customized using an individual patient's own T-cells, which are genetically modified to include a new gene that has a specific protein known as a chimeric antigen receptor, or CAR that directs the T-cells to target and kill leukemia cells that have a specific antigen (called CD19) on the surface.

FDA says the safety and efficacy of Kymriah were demonstrated in one multicenter clinical trial of 63 pediatric and young adult patients with relapsed or refractory B-cell precursor ALL. The overall remission rate within three months of treatment was 83 percent.

"We're entering a new frontier in medical innovation with the ability to reprogram a patient's own cells to attack a deadly cancer," said FDA Commissioner Scott Gottlieb, MD. "New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses."

But the immunotherapy carries a big risk for potentially life-threatening side effects, according to FDA. It could cause cytokine release syndrome, a systemic response to the proliferation of CAR T-cells causing high fever and flu-like symptoms, as well as certain dangerous neurological symptoms.

It's also expensive, at roughly $475,000. That's in addition to traditional chemotherapy, which is administered before the Kymriah with the aim of improving the treatment's success rate.

And because the side effects are potentially so serious, patients will be required to stay within two hours of the 32 hospitals where the immunotherapy is administered, for as long as a month after treatment leading to hefty travel and lodging costs.

Beyond the financial implications, of course, there are significant IT hurdles to overcome, going forward, for widespread and efficient use of personalized medicine.

From data warehousing to EHR design to interoperability, ongoing technology challenges will test IT departments as immunotherapy and other tailored treatments come to the fore.

The research on Kymriah was pioneered at Penn Medicine, for instance, but not before the academic medical center had pursued an extensive retooling of its infrastructure to meet the demands of precision medicine.

"One of the first things we did was to say, look, we're not going to get down this road to precision medicine if we don't have centralized support and a holistic view of IT within the school," Brian Wells, Penn Medicine's then associate vice president of health technology and academic computing, said ahead of the HIMSS and Healthcare IT News Precision Medicine Summit in June of 2017. "The other thing we did was ask, what are the high-priority applications that the school didn't have?

Penn didn't have a common laboratory information management system, for instance, or a common sample management, sample inventory, sample tracking system. Wells said Penn also needed a data warehouse to aggregate all the required information and link it to clinical data so researchers could access it more easily.

Despite the challenges inherent in such a novel treatment, researchers and FDA officials said the promise of this new cellular therapy is very real.

Peter Marks, MD, directory of the FDAs Center for Biologics Evaluation and Research, described Kymirah as a first-of-its-kind treatment for serious disease.

"Not only does Kymriah provide these patients with a new treatment option where very limited options existed, Marks said, but a treatment option that has shown promising remission and survival rates in clinical trials."

And one that IT departments are likely to support in the not-too-distant future.

Twitter:@MikeMiliardHITNEmail the writer: mike.miliard@himssmedia.com

Here is the original post:
In a precision medicine landmark, FDA approves first gene therapy - Healthcare IT News